These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 15883700)

  • 21. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on idiopathic inflammatory myopathies.
    Briani C; Doria A; Sarzi-Puttini P; Dalakas MC
    Autoimmunity; 2006 May; 39(3):161-70. PubMed ID: 16769649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Poxviral immunomodulatory proteins as new therapeutics for immunocorrection].
    Nepomniashchikh TS; Shchelkunov SN
    Mol Biol (Mosk); 2008; 42(5):904-12. PubMed ID: 18988538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. beta-Glycosphingolipids as immune modulators.
    Adar T; Ilan Y
    J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
    Szegedi G
    Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
    Pongratz D
    J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory, immune, and viral aspects of inclusion-body myositis.
    Dalakas MC
    Neurology; 2006 Jan; 66(2 Suppl 1):S33-8. PubMed ID: 16432143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin therapy for autoimmune diseases.
    Arnson Y; Shoenfeld Y; Amital H
    Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of humoral autoimmunity in gastrointestinal neuromuscular diseases.
    Hubball A; Martin JE; Lang B; De Giorgio R; Knowles CH
    Prog Neurobiol; 2009 Jan; 87(1):10-20. PubMed ID: 18929621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding autoimmune disease: new targets for drug discovery.
    Balagué C; Kunkel SL; Godessart N
    Drug Discov Today; 2009 Oct; 14(19-20):926-34. PubMed ID: 19596080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B lymphocytes are required for development and treatment of autoimmune diseases.
    Youinou P; Jamin C; Pers JO; Berthou C; Saraux A; Renaudineau Y
    Ann N Y Acad Sci; 2005 Jun; 1050():19-33. PubMed ID: 16014517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
    Chin LT; Chu C; Chen HM; Wang DW; Liao SK
    Chang Gung Med J; 2008; 31(1):1-15. PubMed ID: 18419049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon alpha and neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2009 Feb; 207(1-2):3-17. PubMed ID: 19171385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dysimmune and inflammatory myopathies].
    Authier FJ
    Rev Prat; 2008 Dec; 58(20):2253-60. PubMed ID: 19209656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases--2008.
    Shoenfeld Y; Blank M; Abu-Shakra M; Amital H; Barzilai O; Berkun Y; Bizzaro N; Gilburd B; Zandman-Goddard G; Katz U; Krause I; Langevitz P; Mackay IR; Orbach H; Ram M; Sherer Y; Toubi E; Gershwin ME
    Isr Med Assoc J; 2008 Jan; 10(1):13-9. PubMed ID: 18300564
    [No Abstract]   [Full Text] [Related]  

  • 37. [Contributions to clinical myology. Clinical immunology].
    Storch W
    Psychiatr Neurol Med Psychol Beih; 1987; 38():71-84. PubMed ID: 3136477
    [No Abstract]   [Full Text] [Related]  

  • 38. CD20: a target antigen for immunotherapy of autoimmune diseases.
    Perosa F; Favoino E; Caragnano MA; Prete M; Dammacco F
    Autoimmun Rev; 2005 Nov; 4(8):526-31. PubMed ID: 16214090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R; Looney RJ
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC; Kaufman HL
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.